215 related articles for article (PubMed ID: 26782353)
21. Early therapy evaluation of combined cetuximab and irinotecan in orthotopic pancreatic tumor xenografts by dynamic contrast-enhanced magnetic resonance imaging.
Kim H; Folks KD; Guo L; Sellers JC; Fineberg NS; Stockard CR; Grizzle WE; Buchsbaum DJ; Morgan DE; George JF; Zinn KR
Mol Imaging; 2011 Jun; 10(3):153-67. PubMed ID: 21496446
[TBL] [Abstract][Full Text] [Related]
22. Afatinib-loaded immunoliposomes functionalized with cetuximab: A novel strategy targeting the epidermal growth factor receptor for treatment of non-small-cell lung cancer.
Lu X; Liu S; Han M; Yang X; Sun K; Wang H; Mu H; Du Y; Wang A; Ni L; Zhang C
Int J Pharm; 2019 Apr; 560():126-135. PubMed ID: 30742982
[TBL] [Abstract][Full Text] [Related]
23. Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors).
Hirokawa Y; Levitzki A; Lessene G; Baell J; Xiao Y; Zhu H; Maruta H
Cancer Lett; 2007 Jan; 245(1-2):242-51. PubMed ID: 16540233
[TBL] [Abstract][Full Text] [Related]
24. Cisplatin-induced antitumor activity is potentiated by the soy isoflavone genistein in BxPC-3 pancreatic tumor xenografts.
Mohammad RM; Banerjee S; Li Y; Aboukameel A; Kucuk O; Sarkar FH
Cancer; 2006 Mar; 106(6):1260-8. PubMed ID: 16475211
[TBL] [Abstract][Full Text] [Related]
25. Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab.
Yamazaki M; Yamashita Y; Kubo N; Yashiro M; Ohira M; Ako E; Tanaka H; Muguruma K; Sawada T; Hirakawa K
Oncol Rep; 2012 Jul; 28(1):49-54. PubMed ID: 22562413
[TBL] [Abstract][Full Text] [Related]
26. IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells.
McMichael EL; Jaime-Ramirez AC; Guenterberg KD; Luedke E; Atwal LS; Campbell AR; Hu Z; Tatum AS; Kondadasula SV; Mo X; Tridandapani S; Bloomston M; Ellison EC; Williams TM; Bekaii-Saab T; Carson WE
Clin Cancer Res; 2017 Jan; 23(2):489-502. PubMed ID: 27435400
[TBL] [Abstract][Full Text] [Related]
27. Estimating preclinical efficacy targets utilizing cetuximab efficacy in KRAS mutant and wild-type colorectal cancer models.
Prewett M; Bassi R; Paz K; Amatulli M; Deevi D; Li H; Wang S; Witte L; Samakoglu S; Tonra JR
Anticancer Res; 2011 Jun; 31(6):2149-60. PubMed ID: 21737635
[TBL] [Abstract][Full Text] [Related]
28. Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cells.
Tanei T; Choi DS; Rodriguez AA; Liang DH; Dobrolecki L; Ghosh M; Landis MD; Chang JC
Breast Cancer Res; 2016 Jan; 18(1):6. PubMed ID: 26757880
[TBL] [Abstract][Full Text] [Related]
29. A Novel Anti-EGFR mAb Ame55 with Lower Toxicity and Better Efficacy than Cetuximab When Combined with Irinotecan.
Qiu W; Zhang C; Wang S; Yu X; Wang Q; Zeng D; Du P; Ma J; Zheng Y; Pang B; Yu Y; Long F; Pang X; Sun Z
J Immunol Res; 2019; 2019():3017360. PubMed ID: 30733972
[TBL] [Abstract][Full Text] [Related]
30. Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status.
Chao MW; Chang LH; Tu HJ; Chang CD; Lai MJ; Chen YY; Liou JP; Teng CM; Pan SL
Clin Epigenetics; 2019 May; 11(1):85. PubMed ID: 31142371
[TBL] [Abstract][Full Text] [Related]
31. High intensity focused ultrasound hyperthermia for enhanced macromolecular delivery.
Frazier N; Payne A; de Bever J; Dillon C; Panda A; Subrahmanyam N; Ghandehari H
J Control Release; 2016 Nov; 241():186-193. PubMed ID: 27686583
[TBL] [Abstract][Full Text] [Related]
32. Designing nanoconjugates to effectively target pancreatic cancer cells in vitro and in vivo.
Khan JA; Kudgus RA; Szabolcs A; Dutta S; Wang E; Cao S; Curran GL; Shah V; Curley S; Mukhopadhyay D; Robertson JD; Bhattacharya R; Mukherjee P
PLoS One; 2011; 6(6):e20347. PubMed ID: 21738572
[TBL] [Abstract][Full Text] [Related]
33. Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models.
Troiani T; Napolitano S; Martini G; Martinelli E; Cardone C; Normanno N; Vitagliano D; Morgillo F; Fenizia F; Lambiase M; Formisano L; Bianco R; Ciardiello D; Ciardiello F
Clin Cancer Res; 2015 Sep; 21(18):4153-64. PubMed ID: 26019172
[TBL] [Abstract][Full Text] [Related]
34. Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for Pancreatic Cancer Therapy.
Li Z; Wang M; Yao X; Luo W; Qu Y; Yu D; Li X; Fang J; Huang C
Target Oncol; 2019 Feb; 14(1):93-105. PubMed ID: 30635821
[TBL] [Abstract][Full Text] [Related]
35. In vitro and in vivo anticancer efficacy of silibinin against human pancreatic cancer BxPC-3 and PANC-1 cells.
Nambiar D; Prajapati V; Agarwal R; Singh RP
Cancer Lett; 2013 Jun; 334(1):109-17. PubMed ID: 23022268
[TBL] [Abstract][Full Text] [Related]
36. Enhanced tumour uptake of radiolabelled antibodies by hyperthermia: Part I: Timing of injection relative to hyperthermia.
Hauck ML; Zalutsky MR
Int J Hyperthermia; 2005 Feb; 21(1):1-11. PubMed ID: 15764347
[TBL] [Abstract][Full Text] [Related]
37. Impact of formulation on the iontophoretic delivery of the FOLFIRINOX regimen for the treatment of pancreatic cancer.
Byrne JD; Jajja MRN; O'Neill AT; Schorzman AN; Keeler AW; Luft JC; Zamboni WC; DeSimone JM; Yeh JJ
Cancer Chemother Pharmacol; 2018 Jun; 81(6):991-998. PubMed ID: 29603014
[TBL] [Abstract][Full Text] [Related]
38. Characterization of Pancreatic Cancer Cell Thermal Response to Heat Ablation or Cryoablation.
Baumann KW; Baust JM; Snyder KK; Baust JG; Van Buskirk RG
Technol Cancer Res Treat; 2017 Aug; 16(4):393-405. PubMed ID: 27340260
[TBL] [Abstract][Full Text] [Related]
39. Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model.
Martin P; Stewart E; Pham NA; Mascaux C; Panchal D; Li M; Kim L; Sakashita S; Wang D; Sykes J; Friess T; Shepherd FA; Liu G; Tsao MS
Clin Lung Cancer; 2016 Sep; 17(5):375-383.e2. PubMed ID: 26926157
[TBL] [Abstract][Full Text] [Related]
40. Combination of sunitinib, cetuximab and irradiation in an orthotopic head and neck cancer model.
Bozec A; Sudaka A; Toussan N; Fischel JL; Etienne-Grimaldi MC; Milano G
Ann Oncol; 2009 Oct; 20(10):1703-7. PubMed ID: 19542251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
